Investors

People are different and so is their cancer, patients should be treated individually.

Presentations

2cureX at Redeye Growth Day 2021


2cureX: CEO Fernando Andreu presents at Redeye Growth Day 2021, 2nd June 2021, Copenhagen.

2cureX at Life Science Investor Conference, ØU Life Science


2cureX: Fernando Andreu and Ole Thastrup presents at Life Science Investor Conference, ØU Life Science, 26th May 2021, Copenhagen.

2cureX at Redeye Investor theme: Medtech & Diagnostics


2cureX CEO Fernando Andreu presents at Medtech & Diagnostics, Stockholm, 4th May 2021 virtual meeting.

2cureX at Redeye Investor Forum, 4th March 2021


2cureX: Fernando Andreu and Ole Thastrup presents at Investor Forum Online 4th May 2021, virtual meeting.
Download accompanying presentation

2cureX Nordnet Interview 2nd March 2021


2cureX CEO Fernando Andreu and CSO Ole Thastrup at Nordnet, 2nd March 2021, virtual meeting.
Download accompanying presentation

2cureX at Redeye Fight Cancer 2021


2cureX CEO Ole Thastrup presents at Fight Cancer 2021, 21st January 2021, virtual meeting.
Download accompanying presentation

2cureX at Redeye Life Science Day 2020


2cureX Ole Thastrup and Maarten van der Linden presents at Redeye Life Science Day 2020, 26th November 2020, Stockholm.

2cureX at Life Science Økonomisk Ugebrev


Ole Thastrup (2cureX CEO) and Maarten van der Linden (2cureX CBO) present at Life Science Økonomisk Ugebrev, 25th November 2020, Copenhagen.

2cureX at Danish Shareholders’ Association (Investor-Ugen)


Ole Thastrup (2cureX CEO) and Maarten van der Linden (2cureX CBO) give latest 2cureX outlook (2021-2023) at Danish Shareholders’ Association (Investor-Ugen), Copenhagen, November 12, 2020.
Download accompanying presentation

Benefits of IndiTreat® Sensitivity Test


Dr. Henrik Harling (2cureX CMO) discussing the dilemma facing the oncologist on the choice of first line colorectal cancer treatment.
Download accompanying presentation

IndiTreat® Sensitivity Test availability


Maarten van der Linden (2cureX CBO) talking about availability and application of IndiTreat® Sensitivity Test for colorectal, pancreatic and ovarian cancer patients.
Download accompanying presentation

2cureX presentation for investors


Ole Thastrup (2cureX CEO) and Maarten van der Linden (2cureX CBO) present 2cureX at Sedermeradagen in Copenhagen on March 11, 2020.

2cureX presentation for investors


Ole Thastrup (2cureX CEO) and Maarten van der Linden (2cureX CBO) present 2cureX at Sedermeradagen in Copenhagen, 2019.

Upcoming events

September 15, 2021 at 15:00 (CET)

Interview with CEO Fernando Andreu (organized by Mangold) Open participation. Details provided later.

Read more

September 23, 2021

CSO Ole Thastrup will speak at the conference “Week of Health and Innovation 2021” in Odense, Denmark

Read more and Register

September 28, 2021

Redeye Medtech & Diagnostics Investor meeting

Read more

September 29, 2021

Mangold Investor Lunch

Read more

IndiTreat® supports genomic characterization of tumors with unique functional information of treatment resistance and sensitivity.